A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

Part of paid clinical trials in Houston, Texas.

Sponsor
Epiphany Biosciences
Study ID
NCT00831103
Phase
PHASE2
Status
Completed

Conditions

  • Herpes Zoster

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • EPB-348 — DRUG
    Treated over seven days
  • Valacyclovir — DRUG
    Treated over seven days

Study Details

The purpose of this study is to determine the pharmacokinetics and dosage of EPB-348 that best balances safety and efficacy among adult immunocompetent patients with an acute episode of herpes zoster.

Key Dates

Start date
Nov 30, 2007
Status verified
Dec 2013
Primary completion
Jun 30, 2009
Completion
Jun 30, 2009

Study Design

Enrollment
373 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: EPB-348 1000 mg
    EPB-348 1000 mg dosed once daily for seven days
  • Experimental: EPB-348 2000 mg
    EPB-348 2000 mg dosed once daily for seven days
  • Experimental: EPB-348 3000 mg
    EPB-348 3000 mg dosed once daily for seven days
  • Active Comparator: Valacyclovir
    Valacyclovir 1000 mg dosed three times daily for seven days

Primary Outcome Measure

To compare the time-to-crusting of vesicles on patients in each of the EPB-348 dosing arms versus the valacyclovir dosing arm. [ Time Frame: Daily assessment during the seven days of treament then weekly until Day 28 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Center for Clinical Studies-Medical CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
Center for Clinical Studies-Medical Center· Houston, TX

Related Studies